The Role of Ki-67 in HR+/HER2- Breast Cancer: A Real-World Study of 956 Patients.
Qin MaYao-Bang LiuTong SheXin-Lan LiuPublished in: Breast cancer (Dove Medical Press) (2024)
In HR+/HER2- breast cancer, patients with Ki-67 > 22.5% have a worse prognosis and are more likely to have early recurrence and metastasis.